Esperion Therapeutics (ESPR) Weakness Overdone Amid FDA AdCom on SNY/REGN's Praluent, UBS UBS analyst Andrew Peters maintained a Buy rating and price target of $140 on Esperion Therapeutics (NASDAQ: ESPR)
CyberArk Files For Secondary Offering After Strong Q1
BY GILLIAN RICH, INVESTOR'S BUSINESS DAILY
6-8-15 08:54 AM ET
CyberArk Software (NASDAQ:CYBR) said Friday it filed for a follow-on stock offering.
The cybersecurity company filed a registration statement with the Securities and Exchange Commission for the secondary offering. The majority of the shares will be sold by current shareholders with $50 million in shares to be sold by CyberArk. The total number of shares to be sold hasn't been decided yet.
Ambarella Earnings Accelerate Further With Drone Growth Seen Adding Boost
Adam Feuerstein @adamfeuerstein now
$PBYI neratinib extenet study gets mediocre review from discussant. Small benefit but toxic.
$ONTY — I’ll write w/ more detail later but updated ‘380 data look good. More responses, including in the brain + no Gr3 diarrhea
big stuff here
ASCO 2015: ( DCTH ) Delcath Systems Shows Life-Extending Results Treating Liver Cancer Patients
By The ASCO Post
Posted: 5/31/2015 8:59 :52 PM
Clinicians continue to produce positive, life-extending results treating liver cancer patients with CHEMOSAT in multiple tumor types
CHEMOSAT is well tolerated and is an easy-to-learn procedure for an experienced treatment teamMultiple treatment courses of at least four procedures have been shown to be safe and well tolerated while continuing to provide clinical benefit and good quality of life
looks great here